作者：
Carmine,Valenza [1]
;
Dario,Trapani [2]
;
Paola,Zagami [3]
;
Gabriele,Antonarelli [4]
;
Luca,Boscolo Bielo [4]
;
Eleonora,Nicolò [5]
;
Joana Mourato,Ribeiro [6]
;
Lorenzo,Guidi [4]
;
Carolina,Reduzzi [5]
;
Martina,Spotti [6]
;
Laura,Adamoli [7]
;
Javier,Cortès [8]
;
Barbara,Pistilli [6]
;
Sara M,Tolaney [9]
;
Naoto,Ueno [10]
;
Rachel M,Layman [11]
;
Massimo,Cristofanilli [5]
;
Lisa A,Carey [12]
;
Elisabetta,Munzone [13]
;
Carmen,Criscitiello [4]
;
Filipa,Lynce [9]
;
Wendy A,Woodward [14]
;
Giuseppe,Curigliano [15]
作者单位：
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Harvard Chan School of Public Health, Harvard University, Boston, MA, USA.
[1]
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: dario.trapani@ieo.it.
[2]
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
[3]
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
[4]
Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.
[5]
Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
[6]
Clinical Trial Office, European Institute of Oncology, IRCCS, Milan, Italy.
[7]
Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City, NJ, USA; International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain; IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain.
[8]
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
[9]
University of Hawai'i Cancer Center, Honolulu, HI, USA.
[10]
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
[11]
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
[12]
Division of Medical Senology, European Institute of Oncology IRCCS, Milan, Italy.
[13]
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
[14]
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
[15]
DOI
10.1016/j.ejca.2024.115097
PMID
39486164
发布时间
2024-12-09
换一批
换一批
